In addition to EGFR, other studies have implicated distinct growth factor signaling pathways as candidate upstream regulators of FOXC1. In one study of FLT3-ITD AML, FOXC1 was highlighted as an upregulated target gene in primary patient samples [68]. The gene discussed is FOXC1; the disease is acute myeloid leukemia.